Hear from your peers at our informal Q&A Sessions to learn more about the difference scalp cooling can make for your patients:

 

Wednesday 11:30am – 12 noon Dr Maryam Lustberg

Thursday 11:30am – 11:45am Dr  Lindsay L. Peterson

Thursday 1pm -2pm Dr. Julie Rani Nangia

Friday 11:30am—11:45am Dr  Lindsay L. Peterson

Friday 1pm -2pm Dr. Julie Rani Nangia

 

Exclusively at booth 706.

 

Dr. Julie Rani Nangia, Assistant Professor of Medicine is a breast medical oncologist at the Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine in Houston, TX.  She is board certified in internal medicine and medical oncology. Dr. Nangia received her medical degree from the University of Missouri-Kansas City. She completed an internal medicine residency at The University of Texas Health Science Center in Houston as well as a hematology-oncology fellowship at Rush University Medical Center in Chicago, IL. Dr. Nangia specializes in the care of patients with breast cancer or at high risk to develop breast cancer.  She is the Director of the Breast Cancer Prevention and High Risk Program at Baylor College of Medicine and has a special interest in hereditary breast cancer, breast cancer prevention and triple negative breast cancer.  She is also the medical director of the Breast Care Center at Smith Clinic and Ben Taub General Hospital.  Her research interests are in breast cancer prevention, metastatic triple negative breast cancer, understanding mechanisms of metastatic breast cancer and prevention of chemotherapy-induced alopecia.  She is the principal investigator of many institutional, national and global trials and is currently the national PI on 2 multi-site investigator initiated clinical trials.  She is international most well known for her research with scalp cooling for the prevention of chemotherapy-induced alopecia and was the national PI for the SCALP trial which is the only randomized clinical trial with scalp cooling devices in the world and led to FDA clearance of a scalp cooling device in the US.

 

Dr Maryam Lustberg is an associate professor on the tenure track in the Division of Medical Oncology at The Ohio State University, where she specialize in treating patients with breast cancer at The Ohio State’s Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James).

Her research focuses on improving long-term outcomes for breast cancer patients who have developed side effects associated with treatment, and on investigating novel blood-based biomarkers to identify recurrence and treatment toxicity earlier. She joined the Division of Medical Oncology in August 2010 after completing a two-year internal medicine residency at the University of Maryland and a three-year combined medical oncology and breast medical oncology fellowship at Ohio State (2007-2010). She also obtained a Master’s of Public Health (MPH) in Clinical Investigation from Ohio State’s College of Public Health in 2010. She obtained her medical degree from the University of Maryland in 2003.

She serves as the medical director of supportive care for the OSUCCC – James and as director for breast cancer survivorship for The Stefanie Spielman Comprehensive Breast Center. In addition, she chairs the Breast Cancer Survivorship Care Committee and is involved in community events that increase public awareness of breast cancer and survivorship issues. She is physician champion for supportive care services focusing on expanding research, clinical care and programs for this group.

 

Lindsay L. Peterson, MD, MSCR is a breast oncologist at Washington University School of Medicine. She received her MD from Tulane University School of Medicine and completed her residency and fellowship at the University of Texas Health Science Center at San Antonio. Her research interests center around improving outcomes in breast cancer patients through lifestyle modifications, including diet and exercise, as well as helping patients maintain their quality of life during and after cancer therapy. She is the site PI for multiple phase III breast cancer clinical trials as well as investigator initiated trials of lifestyle interventions in breast cancer.